Filing Details

Accession Number:
0001209191-23-051934
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-04 16:15:17
Reporting Period:
2023-10-02
Accepted Time:
2023-10-04 16:15:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1426800 Assembly Biosciences Inc. ASMB Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1993254 S Nicole White C/O Assembly Biosciences, Inc.
331 Oyster Point Blvd., Fourth Floor
South San Francisco CA 94080
Chief Manufacturing Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-10-02 10,000 $0.00 96,142 No 4 A Direct
Common Stock Disposition 2023-10-03 1,891 $0.80 94,251 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. Represents shares of common stock issuable under a performance-based restricted stock unit award dated August 1, 2022. On October 2, 2023, a performance-based vesting condition was achieved. These shares of common stock vest in two equal installments, assuming continuous service on each vesting date, as follows: October 2, 2023 and October 2, 2024.
  2. The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.79 to $0.83, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.